New pill combo aims to delay chemo in advanced breast cancer

NCT ID NCT07647328

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 22, 2026 · Last updated Jun 24, 2026 · Updated 1 time

Summary

This phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take the pills daily until their cancer progresses or side effects become too much.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Duarte, California, 91010, United States
Research Site

Palo Alto, California, 94304, United States
Research Site

Marietta, Georgia, 30060, United States
Research Site

Evanston, Illinois, 60201, United States
Research Site

Edgewood, Kentucky, 41017, United States
Research Site

Louisville, Kentucky, 40202, United States
Research Site

Reno, Nevada, 89502, United States
Research Site

Sioux Falls, South Dakota, 57105, United States
Research Site

Nashville, Tennessee, 37204, United States
Research Site

Fort Worth, Texas, 76104, United States
Research Site

Kingwood, Texas, 77339, United States
Research Site

Midlothian, Virginia, 23114, United States
Research Site

Angers, 49933, France
Research Site

Bayonne, 64109, France
Research Site

Bobigny, 93000, France
Research Site

Caen, 14000, France
Research Site

Chambray-lès-Tours, 37170, France
Research Site

Grenoble, 38043, France
Research Site

Montpellier, 34070, France
Research Site

Nancy, 54100, France
Research Site

Nîmes, 30029, France
Research Site

Pierre-Bénite, 69310, France
Research Site

Valenciennes, 59300, France
Research Site

Vandœuvre-lès-Nancy, 54519, France
Research Site

Villejuif, 94805, France
Research Site

Berlin, 13125, Germany
Research Site

Düsseldorf, 40235, Germany
Research Site

Freiburg im Breisgau, 79110, Germany
Research Site

Mönchengladbach, 41061, Germany
Research Site

München, 81675, Germany
Research Site

Paderborn, 33098, Germany
Research Site

Trier, 54290, Germany
Research Site

Velbert, 42551, Germany
Research Site

Aviano, 33081, Italy
Research Site

Bergamo, 24127, Italy
Research Site

Genova, 16132, Italy
Research Site

Milan, 20127, Italy
Research Site

Naples, 80131, Italy
Research Site

Gdansk, 80-952, Poland
Research Site

Konin, 62-500, Poland
Research Site

Krakow, 30-688, Poland
Research Site

Lodz, 90-302, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Poznan, 61-485, Poland
Research Site

Przemyśl, 37-700, Poland
Research Site

Wroclaw, 53-413, Poland
Research Site

Cheonan-si, 31151, South Korea
Research Site

Daegu, 42415, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Hwasun-eup, 58128, South Korea
Research Site

Incheon, 405-760, South Korea
Research Site

Seongbuk-Gu, 02841, South Korea
Research Site

Seongnam-si, 13520, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Seoul, 07985, South Korea
Research Site

Seoul, 3722, South Korea
Research Site

Songpa-gu, 05505, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Badajoz, 06080, Spain
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 08041, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Huelva, 21005, Spain
Research Site

Jaén, 23007, Spain
Research Site

Las Palmas de Gran Canaria, 35016, Spain
Research Site

Majadahonda, 28222, Spain
Research Site

Málaga, 29010, Spain
Research Site

Murcia, 30008, Spain
Research Site

Pontevedra, 36312, Spain
Research Site

Pozuelo de Alarcón, 28223, Spain
Research Site

Santander, 39008, Spain
Research Site

Toledo, 45007, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Basel, 4031, Switzerland
Research Site

Liestal, CH-4410, Switzerland
Research Site

Rennaz, 1847, Switzerland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

camizestrant and ribociclib (oral tablets)

What this could lead to

If successful, this combination could offer a new first-line treatment option that delays the need for further chemotherapy in advanced breast cancer.

What could go wrong

This is a single-arm, open-label study without a placebo group, so results may be less definitive. Side effects from the drug combination are possible, and the trial is still recruiting.

Conditions

The condition(s) this trial relates to.

Breast Diseases Breast Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER-POSITIVE, HER2-NEGATIVE BREAST CANCER